Inovio Pharmaceuticals Inc (INO) : Round Table Services scooped up 56,000 additional shares in Inovio Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 25, 2016. The investment management firm now holds a total of 129,500 shares of Inovio Pharmaceuticals Inc which is valued at $1,249,675.Inovio Pharmaceuticals Inc makes up approximately 0.69% of Round Table Services’s portfolio.
Other Hedge Funds, Including , Financial Architects Inc added INO to its portfolio by purchasing 50 company shares during the most recent quarter which is valued at $483. Advocacy Wealth Management Services added INO to its portfolio by purchasing 1,250 company shares during the most recent quarter which is valued at $22,725. Inovio Pharmaceuticals Inc makes up approx 0.01% of Advocacy Wealth Management Services’s portfolio.Cutler Group Lp reduced its stake in INO by selling 3,274 shares or 45.66% in the most recent quarter. The Hedge Fund company now holds 3,896 shares of INO which is valued at $33,817. Bnp Paribas Arbitrage Sa added INO to its portfolio by purchasing 2,574 company shares during the most recent quarter which is valued at $23,449.
Inovio Pharmaceuticals Inc opened for trading at $9.54 and hit $9.93 on the upside on Friday, eventually ending the session at $9.88, with a gain of 2.70% or 0.26 points. The heightened volatility saw the trading volume jump to 14,87,852 shares. Company has a market cap of $722 M.
Inovio Pharmaceuticals Inc. (Inovio) is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. As of December 31 2014 Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers prostate cancer breast/lung/pancreatic cancer hepatitis C virus (HCV) hepatitis B virus (HBV) HIV influenza and Ebola. With its immunotherapy platform consisting of SynCon products as well as its CELLECTRA electroporation delivery technology Inovio has developed a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovio’s immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.